IRIS
SCARFO', LYDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.773
NA - Nord America 2.643
EU - Europa 1.188
SA - Sud America 835
AF - Africa 35
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.492
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.561
SG - Singapore 1.080
CN - Cina 804
BR - Brasile 701
HK - Hong Kong 506
SE - Svezia 337
IT - Italia 227
VN - Vietnam 177
DE - Germania 153
RU - Federazione Russa 112
GB - Regno Unito 64
AR - Argentina 63
FI - Finlandia 62
AT - Austria 36
MX - Messico 35
CA - Canada 34
IN - India 34
EC - Ecuador 29
FR - Francia 28
PL - Polonia 28
NL - Olanda 27
ID - Indonesia 25
BD - Bangladesh 23
IQ - Iraq 23
IE - Irlanda 22
JP - Giappone 21
ES - Italia 18
AU - Australia 17
BE - Belgio 16
GR - Grecia 16
CO - Colombia 13
ZA - Sudafrica 13
PY - Paraguay 12
AE - Emirati Arabi Uniti 11
PK - Pakistan 11
VE - Venezuela 10
TR - Turchia 9
UA - Ucraina 9
IL - Israele 7
UZ - Uzbekistan 7
LT - Lituania 6
NO - Norvegia 6
KE - Kenya 5
MA - Marocco 5
SA - Arabia Saudita 5
ET - Etiopia 4
LU - Lussemburgo 4
PA - Panama 4
TN - Tunisia 4
AL - Albania 3
BB - Barbados 3
BH - Bahrain 3
DK - Danimarca 3
JO - Giordania 3
KR - Corea 3
KZ - Kazakistan 3
UY - Uruguay 3
AZ - Azerbaigian 2
CL - Cile 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
EG - Egitto 2
IR - Iran 2
LB - Libano 2
LV - Lettonia 2
MY - Malesia 2
RS - Serbia 2
TW - Taiwan 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
ML - Mali 1
NA - Namibia 1
NP - Nepal 1
OM - Oman 1
PE - Perù 1
PH - Filippine 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.492
Salva come PNG Salva come JPEG
Città #
Dallas 1.385
Singapore 520
Hong Kong 504
Ashburn 254
Shanghai 219
Hefei 148
Beijing 130
Lawrence 97
Princeton 97
New York 87
Milan 72
Ho Chi Minh City 65
Moscow 58
Los Angeles 53
São Paulo 51
Nuremberg 49
Munich 44
Boardman 40
Hanoi 30
Rome 25
Warsaw 25
Helsinki 24
Dublin 22
Rio de Janeiro 20
Turku 20
Tokyo 19
Vienna 19
Boston 16
Guangzhou 16
Brooklyn 15
Houston 15
Montreal 15
Brasília 14
Denver 14
Lappeenranta 14
Thessaloniki 14
Chennai 13
Poplar 13
Porto Alegre 12
Belo Horizonte 11
Orem 11
Stockholm 11
Brussels 10
Buffalo 10
Curitiba 10
London 10
Manchester 10
Monza 10
Phoenix 10
Shenzhen 10
Atlanta 9
Baghdad 9
Chicago 9
Columbus 9
Da Nang 9
Frankfurt am Main 9
Guarulhos 9
Hangzhou 9
Quito 9
Toronto 9
Amsterdam 8
Asunción 8
Dubai 8
Johannesburg 8
Oviedo 8
Querétaro 8
Ribeirão Preto 8
The Dalles 8
Biên Hòa 7
Florianópolis 7
Jakarta 7
Mexico City 7
Ninh Bình 7
San Francisco 7
Wuxi 7
Buenos Aires 6
Goiânia 6
Haiphong 6
Jiaxing 6
Manaus 6
Mol 6
Santa Clara 6
Tashkent 6
Wollongong 6
Ankara 5
Caraguatatuba 5
Cleveland 5
Guayaquil 5
Ipatinga 5
Nairobi 5
Naples 5
Osasco 5
Praia Grande 5
Seattle 5
Sorocaba 5
Sydney 5
Vitória 5
Wolfhagen 5
Zhengzhou 5
Accrington 4
Totale 4.697
Salva come PNG Salva come JPEG
Nome #
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 401
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice: Lymphoma 391
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker: CHRONIC LYMPHOCYTIC LEUKEMIA 371
Exploring Perceptions, Opinions, and Needs of Adult and Pediatric Cancer Patients, Caregivers, and Healthcare Professionals Towards Low-Fidelity Versions of the MyPal Project's Applications: Findings from 12 Pre-Pilot Focus Groups in 4 European Countries of an ePRO Intervention for Palliative Cancer Care (Preprint) 142
Chronic lymphocytic leukaemia 103
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 97
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 97
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 93
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 81
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 81
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 79
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 77
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 73
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 68
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 67
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 67
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 67
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL 66
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 65
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 63
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 62
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 61
Targeting B-cell anergy in chronic lymphocytic leukemia. 60
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 59
3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells 59
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 58
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 58
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 58
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 57
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL 56
CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL 56
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia 56
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 56
Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death 55
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study 54
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 54
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 53
T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations 52
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target 51
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial 51
Monoclonal B lymphocytosis in the general population 51
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 50
Reprogramming cell death: BCL2 family inhibition in hematological malignancies 50
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 50
COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now 49
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 49
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 49
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia 49
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia 49
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 48
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 48
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL 48
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia 47
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 47
Profiling the Genomic Landscape at the Early Stages of CLL: Low Genomic Complexity and Paucity of Driver Mutations in MBL and Indolent CLL 47
CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? 46
Infrequent "chronic lymphocytic leukemia-specific" immunoglobulin stereotypes in aged individuals with or without low count monoclonal B cell lymphocytosis 46
Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients 46
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 45
MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27 44
Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia 44
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities 44
Single cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib 44
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience 44
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 43
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 43
Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia 43
Monoclonal B Cell Lymphocytosis in Hepatitis C Virus Infected Individuals 43
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment 43
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 42
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia 42
Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia 42
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia 42
MyPal-Child study protocol: An observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients 42
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 41
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study) 41
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 41
Relevance of Minimal Residual Disease in the Era of Targeted Agents 41
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy 41
Prognostic relevance of MYD88 mutations in CLL: the jury is still out 40
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors 40
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia 40
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study 40
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy 39
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 39
Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control 39
Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) 38
Co-Designing Smartphone Notifications According to the Clinical Routine of Cancer Patients 38
The inhibitory receptor toll interleukin-1R 8 (TIR8/IL-1R8/SIGIRR) is downregulated in chronic lymphocytic leukemia 38
High-throughput analysis of the T-cell receptor gene repertoire in low-count monoclonal B-cell lymphocytosis reveals a distinct profile from chronic lymphocytic leukemia 38
Loss of CYLD promotes splenic marginal zone lymphoma 37
Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia 37
Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia - Time to Retire? 37
Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography 37
MyPal ADULT study protocol: A randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies 37
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling 36
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 36
Toll-Like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation 36
IgG-Switched CLL Has a Distinct Immunogenetic Signature from the Common MD Variant: Ontogenetic Implications 35
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL 35
Totale 6.231
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.101
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.101
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 5 4 0 0 0 0 0
2021/202275 0 0 0 21 6 3 8 19 7 6 2 3
2022/2023616 215 113 54 1 16 82 23 34 40 8 11 19
2023/2024477 13 20 27 119 22 71 4 27 1 12 44 117
2024/20252.285 276 53 63 60 87 164 243 215 393 340 182 209
2025/20264.200 544 1.018 1.056 992 542 48 0 0 0 0 0 0
Totale 7.747